{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T02:02:59Z","timestamp":1790906579037,"version":"4.1.0"},"reference-count":49,"publisher":"BMJ","issue":"4","license":[{"start":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T00:00:00Z","timestamp":1712707200000},"content-version":"unspecified","delay-in-days":9,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Immunother Cancer"],"accepted":{"date-parts":[[2024,2,5]]},"published-print":{"date-parts":[[2024,4]]},"abstract":"<jats:p>With an increasing number of patients eligible for immune checkpoint inhibitors, the incidence of immune-related adverse events (irAEs) is on the rise. Dermatologic immune-related adverse events (D-irAEs) are the most common and earliest to manifest, often with important downstream consequences for the patient. Current guidelines lack clarity in terms of diagnostic criteria for D-irAEs. The goal of this project is to better define D-irAE for the purposes of identification, diagnosis, and future study of this important group of diseases.<\/jats:p>\n               <jats:p>The objectives of this project were to develop consensus guidance for an approach to D-irAEs including disease definitions and severity grading. Knowing that consensus among oncologists, dermatologists, and irAE subspecialists would be critical for usability, we formed a Dermatologic irAE Disease Definition Panel. The panel was composed of 34 experts, including oncologists, dermatologists, a rheumatologist, and an allergist\/immunologist from 22 institutions across the USA and internationally. A modified Delphi consensus process was used, with two rounds of anonymous ratings by panelists and two virtual meetings to discuss areas of controversy. Panelists rated content for usability, appropriateness, and accuracy on 9-point scales in electronic surveys and provided free text comments. A working group aggregated survey responses and incorporated them into revised definitions. Consensus was based on numeric ratings using the RAND\/UCLA Appropriateness Method with prespecified definitions.<\/jats:p>\n               <jats:p>Following revisions based on panelist feedback, all items received consensus in the second round of ratings. Consensus definitions were achieved for 10 core D-irAE diagnoses: ICI-vitiligo, ICI-lichen planus, ICI-psoriasis, ICI-exanthem, ICI-bullous pemphigoid, ICI-Grover\u2019s, ICI-eczematous, ICI-eruptive atypical squamous proliferation, ICI-pruritus without rash, and ICI-erosive mucocutaneous. A standard evaluation for D-irAE was also found to reach consensus, with disease-specific exceptions detailed when necessary. Each disorder\u2019s description includes further details on disease subtypes, symptoms, supportive exam findings, and three levels of diagnostic certainty (definite, probable, and possible).<\/jats:p>\n               <jats:p>These consensus-driven disease definitions standardize D-irAE classification in a useable framework for multiple disciplines and will be the foundation for future work. Given consensus on their accuracy and usability from a representative panel group, we anticipate that they can be used broadly across clinical and research settings.<\/jats:p>","DOI":"10.1136\/jitc-2023-007675","type":"journal-article","created":{"date-parts":[[2024,4,10]],"date-time":"2024-04-10T13:26:09Z","timestamp":1712755569000},"page":"e007675","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":35,"title":["Defining D-irAEs: consensus-based disease definitions for the diagnosis of dermatologic adverse events from immune checkpoint inhibitor therapy"],"prefix":"10.1136","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8844-3284","authenticated-orcid":false,"given":"Steven T","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Mass General Cancer Center, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7387-3094","authenticated-orcid":false,"given":"Yevgeniy R","family":"Semenov","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Massachusetts General Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allireza","family":"Alloo","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Q","family":"Bach","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Cedars Sinai, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6422-2997","authenticated-orcid":false,"given":"Allison","family":"Betof Warner","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amina","family":"Bougrine","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Universit\u00e9 de Montr\u00e9al, Montreal, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leeann","family":"Burton","sequence":"additional","affiliation":[{"name":"Biogen Inc, Cambridge, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura C","family":"Cappelli","sequence":"additional","affiliation":[{"name":"Johns Hopkins University School of Medicine, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Castells","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medicine, Division of Allergy and Clinical Immunology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justine","family":"Cohen","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medical Oncology, Centers for Cutaneous and Melanoma Oncology, Dana-Farber Cancer Insititute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna K","family":"Dewan","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riley","family":"Fadden","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Guggina","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6616-4882","authenticated-orcid":false,"given":"Aparna","family":"Hegde","sequence":"additional","affiliation":[{"name":"UAB, Birmingham, Alabama, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of California Davis, Davis, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas B","family":"Johnson","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Nashville, Tennessee, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Kaffenberger","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ohio State University Wexner Medical Center, Columbus, Ohio, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Kroshinsky","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Duke University Medical Center, Durham, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shawn","family":"Kwatra","sequence":"additional","affiliation":[{"name":"Johns Hopkins Department of Dermatology, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernice","family":"Kwong","sequence":"additional","affiliation":[{"name":"Stanford University School of Medicine, Stanford, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario E","family":"Lacouture","sequence":"additional","affiliation":[{"name":"MSKCC, New York, New York, USA"},{"name":"NYU Langone Health, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Larocca","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alina","family":"Markova","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"McDunn","sequence":"additional","affiliation":[{"name":"Project Data Sphere \u00ae, Morrisville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8289-8015","authenticated-orcid":false,"given":"Meghan J","family":"Mooradian","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3470-8686","authenticated-orcid":false,"given":"Jarushka","family":"Naidoo","sequence":"additional","affiliation":[{"name":"Johns Hopkins University, The Bloomberg-Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Choi","sequence":"additional","affiliation":[{"name":"Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Nambudiri","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline A","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5372-784X","authenticated-orcid":false,"given":"Anisha B","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Internal Medicine, University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Pimkina","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johnathan","family":"Rine","sequence":"additional","affiliation":[{"name":"Project Data Sphere \u00ae, Morrisville, North Carolina, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista M","family":"Rubin","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxwell","family":"Sauder","sequence":"additional","affiliation":[{"name":"DIvision of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheila","family":"Shaigany","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra\/Northwell, Hempstead, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afreen","family":"Shariff","sequence":"additional","affiliation":[{"name":"Department of Medicine, Duke University School of Medicine, Durham, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5344-6645","authenticated-orcid":false,"given":"Ryan J","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4226-7443","authenticated-orcid":false,"given":"Leyre","family":"Zubiri","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7793-654X","authenticated-orcid":false,"given":"Kerry L","family":"Reynolds","sequence":"additional","affiliation":[{"name":"Mass General Cancer Center, Boston, MA, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Massachusetts General Hospital, Boston, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8264-834X","authenticated-orcid":false,"given":"Nicole R","family":"LeBoeuf","sequence":"additional","affiliation":[{"name":"Harvard Medical School, Boston, Massachusetts, USA"},{"name":"Department of Dermatology, Brigham and Women\u2019s Hospital, Boston, Massachusetts, USA"},{"name":"Center for Cutaneous Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,4,10]]},"reference":[{"key":"2025100306540695000_12.4.e007675.1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/j.jaad.2021.03.094","article-title":"Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-Checkpoint inhibitors: A United States population-level analysis","volume":"86","author":"Wongvibulsin","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.2","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-018-0316-z","article-title":"Development of PD-1 and PD-L1 inhibitors as a form of cancer Immunotherapy: a comprehensive review of registration trials and future considerations","volume":"6","author":"Gong","year":"2018","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor Immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025100306540695000_12.4.e007675.4","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.jaad.2020.04.105","article-title":"Dermatologic toxicities to immune Checkpoint inhibitor therapy: A review of histopathologic features","volume":"83","author":"Ellis","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.5","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596"},{"key":"2025100306540695000_12.4.e007675.6","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"2025100306540695000_12.4.e007675.7","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jaad.2020.03.132","article-title":"Immune Checkpoint inhibitor-related Dermatologic adverse events","volume":"83","author":"Geisler","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.8","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-017-0300-z","article-title":"Managing toxicities associated with immune Checkpoint inhibitors: consensus recommendations from the society for Immunotherapy of cancer (SITC)","volume":"5","author":"Puzanov","year":"2017","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.003"},{"key":"2025100306540695000_12.4.e007675.10","doi-asserted-by":"crossref","DOI":"10.1177\/1758835918764628","article-title":"Clinical assessment of immune-related adverse events","volume":"10","author":"Sosa","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"2025100306540695000_12.4.e007675.11","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1200\/EDBK_289911","article-title":"Dermatologic adverse events of systemic anticancer therapies: cytotoxic chemotherapy, targeted therapy, and Immunotherapy","volume":"40","author":"Deutsch","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"2025100306540695000_12.4.e007675.12","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1111\/bjd.19750","article-title":"Cutaneous immune-related adverse events in patients with Melanoma treated with Checkpoint inhibitors","volume":"185","author":"Gault","year":"2021","journal-title":"Br J Dermatol"},{"key":"2025100306540695000_12.4.e007675.13","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of cancer (SITC) clinical practice guideline on immune Checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.14","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune Checkpoint inhibitors","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw Open"},{"key":"2025100306540695000_12.4.e007675.15","doi-asserted-by":"crossref","first-page":"4986","DOI":"10.1002\/cam4.2397","article-title":"Colitis after Checkpoint blockade: A retrospective cohort study of Melanoma patients requiring admission for symptom control","volume":"8","author":"Hughes","year":"2019","journal-title":"Cancer Med"},{"key":"2025100306540695000_12.4.e007675.16","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002890","article-title":"Consensus disease definitions for neurologic immune-related adverse events of immune Checkpoint inhibitors","volume":"9","author":"Guidon","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2018.10.062"},{"key":"2025100306540695000_12.4.e007675.18","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1203475420943260","article-title":"Cutaneous immune-related adverse events (irAEs) to immune Checkpoint inhibitors: A Dermatology perspective on management","volume":"25","author":"Muntyanu","year":"2021","journal-title":"J Cutan Med Surg"},{"key":"2025100306540695000_12.4.e007675.19","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"2025100306540695000_12.4.e007675.20","unstructured":"Sphere PD . Immune-related adverse events. 2021. Available: https:\/\/www.projectdatasphere.org\/research\/programs\/immune-related-adverse-events"},{"key":"2025100306540695000_12.4.e007675.21","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002896","article-title":"Immune-related adverse events associated with immune Checkpoint inhibitors: a call to action for collecting and sharing clinical trial and real-world data","volume":"9","author":"Reynolds","year":"2021","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.22","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1016\/j.jid.2022.04.020","article-title":"Cutaneous toxicities associated with immune Checkpoint inhibitors: an observational, Pharmacovigilance study","volume":"142","author":"Le","year":"2022","journal-title":"J Invest Dermatol"},{"key":"2025100306540695000_12.4.e007675.23","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1001\/jamaoncol.2020.5012","article-title":"Multisystem immune-related adverse events associated with immune Checkpoint inhibitors for treatment of non-small cell lung cancer","volume":"6","author":"Shankar","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025100306540695000_12.4.e007675.24","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.jaad.2019.12.068","article-title":"Bullous Pemphigoid after anti-programmed Death-1 therapy: A retrospective case-control study evaluating impact on tumor response and survival outcomes","volume":"87","author":"Nelson","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.25","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1016\/j.jaad.2020.10.054","article-title":"De Novo cutaneous connective tissue disease temporally associated with immune Checkpoint inhibitor therapy: A retrospective analysis","volume":"84","author":"Bui","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.26","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-019-0821-8","article-title":"Worsening and newly diagnosed Paraneoplastic syndromes following anti-PD-1 or anti-PD-L1 Immunotherapies, a descriptive study","volume":"7","author":"Manson","year":"2019","journal-title":"J Immunother Cancer"},{"key":"2025100306540695000_12.4.e007675.27","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2019.00249","article-title":"Paraneoplastic Pemphigus revealed by anti-programmed Death-1 Pembrolizumab therapy for cutaneous squamous cell carcinoma complicating Hidradenitis Suppurativa","volume":"6","author":"Yatim","year":"2019","journal-title":"Front Med (Lausanne)"},{"key":"2025100306540695000_12.4.e007675.28","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0769-1"},{"key":"2025100306540695000_12.4.e007675.29","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1111\/bjd.19313","article-title":"Diagnostic and therapeutic differences between immune Checkpoint inhibitor-induced and idiopathic Bullous Pemphigoid: a cross-sectional study","volume":"183","author":"Molina","year":"2020","journal-title":"Br J Dermatol"},{"key":"2025100306540695000_12.4.e007675.30","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1007\/s00403-023-02577-7","article-title":"Immune Checkpoint inhibitor-induced Vitiligo in cancer patients: characterization and management","volume":"315","author":"Lo","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025100306540695000_12.4.e007675.31","first-page":"97","article-title":"Vitiligo-like Depigmentation patterns in patients receiving Immunotherapy for metastatic Melanoma","volume":"156","author":"Zottarelli","year":"2021","journal-title":"Ital J Dermatol Venerol"},{"key":"2025100306540695000_12.4.e007675.32","doi-asserted-by":"crossref","first-page":"e283","DOI":"10.1016\/j.jaad.2019.08.064","article-title":"365-nM Narrowband wood\u2019s lamp for Vitiligo and Hypopigmentation disorders","volume":"83","author":"Bae","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.33","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/742826","article-title":"Cutaneous and Mucosal Lichen Planus: a comprehensive review of clinical subtypes, risk factors, diagnosis, and prognosis","volume":"2014","author":"Gorouhi","year":"2014","journal-title":"ScientificWorldJournal"},{"key":"2025100306540695000_12.4.e007675.34","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/cup.14299","article-title":"Lichen-Planus-Pemphigoides-like reaction to PD-1 Checkpoint blockade","volume":"49","author":"Wat","year":"2022","journal-title":"J Cutan Pathol"},{"key":"2025100306540695000_12.4.e007675.35","doi-asserted-by":"crossref","first-page":"934093","DOI":"10.3389\/fonc.2022.934093","article-title":"Immune Checkpoint inhibitors in the treatment of patients with cancer and preexisting psoriasis: A systematic review and meta-analysis of observational studies","volume":"12","author":"Yu","year":"2022","journal-title":"Front Oncol"},{"key":"2025100306540695000_12.4.e007675.36","doi-asserted-by":"crossref","unstructured":"Verspohl SH , Holderried T , Behning C , et al . Prevalence, therapy and tumour response in patients with rheumatic immune-related adverse events following immune Checkpoint inhibitor therapy: a single-centre analysis. Ther Adv Musculoskelet Dis 2021;13. doi:10.1177\/1759720X211006963","DOI":"10.1177\/1759720X211006963"},{"key":"2025100306540695000_12.4.e007675.37","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61909-7"},{"key":"2025100306540695000_12.4.e007675.38","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1111\/jdv.14011","article-title":"Anti-Pd1-induced psoriasis: a study of 21 patients","volume":"31","author":"Bonigen","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025100306540695000_12.4.e007675.39","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1177\/12034754221128796","article-title":"Utilization of the psoriasis epidemiology screening tool (PEST): A risk stratification strategy for early referral of Psoriatic arthritis patients to minimize irreversible erosive joint damage","volume":"26","author":"Chang","year":"2022","journal-title":"J Cutan Med Surg"},{"key":"2025100306540695000_12.4.e007675.40","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2012.41.6750"},{"key":"2025100306540695000_12.4.e007675.41","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/ijd.13984","article-title":"A review of Bullous Pemphigoid associated with PD-1 and PD-L1 inhibitors","volume":"57","author":"Lopez","year":"2018","journal-title":"Int J Dermatol"},{"key":"2025100306540695000_12.4.e007675.42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/j.jaad.2022.06.1186","article-title":"Impact of biologic therapy on cancer outcomes in patients with immune Checkpoint inhibitor-induced Bullous Pemphigoid","volume":"88","author":"Said","year":"2023","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.43","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1111\/cup.13312","article-title":"Suprabasal Acantholytic Dermatologic toxicities associated Checkpoint inhibitor therapy: A spectrum of immune reactions from Paraneoplastic Pemphigus-like to Grover-like lesions","volume":"45","author":"Chen","year":"2018","journal-title":"J Cutan Pathol"},{"key":"2025100306540695000_12.4.e007675.44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jaad.2015.10.029","article-title":"Cutaneous adverse events (Aes) of anti-programmed cell death (PD)-1 therapy in patients with metastatic Melanoma: A single-institution cohort","volume":"74","author":"Hwang","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.45","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.jaad.2018.10.014","article-title":"Eruptive squamous Atypia (also known as Eruptive Keratoacanthoma): definition of the disease entity and successful management via Intralesional 5-fluorouracil","volume":"81","author":"Que","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.46","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1007\/s00403-022-02468-3","article-title":"To treat or not to treat: PD-L1 inhibitor-induced Keratoacanthoma and squamous cell carcinoma","volume":"315","author":"Poole","year":"2023","journal-title":"Arch Dermatol Res"},{"key":"2025100306540695000_12.4.e007675.47","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1016\/j.jaad.2020.03.029","article-title":"Generalized Bullous Mucocutaneous eruption mimicking Stevens-Johnson syndrome in the setting of immune Checkpoint inhibition: A multicenter case series","volume":"83","author":"Molina","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025100306540695000_12.4.e007675.48","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1001\/jamadermatol.2021.5476","article-title":"Association of cutaneous immune-related adverse events with increased survival in patients treated with anti-programmed cell death 1 and anti-programmed cell death ligand 1 therapy","volume":"158","author":"Tang","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2025100306540695000_12.4.e007675.49","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1001\/jamadermatol.2021.0326","article-title":"Patterns of cutaneous and Noncutaneous immune-related adverse events among patients with advanced cancer","volume":"157","author":"Thompson","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jitc-2023-007675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T13:54:21Z","timestamp":1759499661000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1136\/jitc-2023-007675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4]]},"references-count":49,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,4,10]]},"published-print":{"date-parts":[[2024,4]]}},"alternative-id":["10.1136\/jitc-2023-007675"],"URL":"https:\/\/doi.org\/10.1136\/jitc-2023-007675","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,4]]}}}